natgillin/translations-raw huggingface dataset:
Following coadministration of dapagliflozin with mefenamic acid (an inhibitor of UGT1A9), a 55% increase in dapagliflozin systemic exposure was seen, but with no clinically meaningful effect on 24-hour urinary glucose excretion.
Nakon istodobne primjene dapagliflozina i mefenaminske kiseline (inhibitora UGT1A9) zabilježeno je povećanje sistemske izloženosti dapagliflozinu od 55%, ali nije bilo klinički značajnog učinka na 24- satno izlučivanje glukoze mokraćom.
Following coadministration of the ABCB1 (P-gp) and ABCG2 (BCRP) inhibitor, elacridar (GF120918) at 100 to 1,000 mg with oral topotecan, the AUC0-∞ of topotecan lactone and total topotecan increased approximately 2.5-fold (see section 4.5 for guidance).
Nakon istodobne primjene inhibitora ABCB1 (P-gp) i ABCG2 (BCRP), elakridara (GF120918), u dozi od 100 do 1000 mg s oralnim topotekanom, AUC 0-∞ topotekan laktona i ukupnog topotekana narasla je približno 2,5 puta, (vidjeti dio 4.5).
Following completion of INCIVO therapy contraceptive recommendations should be followed as in the Summary of Product Characteristics for ribavirin, and as described below.
Nakon završetka liječenja INCIVOM treba se pridržavati preporuka za kontracepciju koje su navedene u Sažetku opisa svojstava lijeka za ribavirin i u daljnjem tekstu.
Following completion of the 12-week placebo-controlled phase of the studies, all subjects were switched to Feraccru 30 mg twice daily open-label treatment for a further 52 weeks.
Nakon dovršetka placebom kontrolirane faze studije u trajanju od 12 tjedana, svi su ispitanici prebačeni na liječenje Feraccruom u dozi od 30 mg dvaput dnevno u dodatnom razdoblju od 52 tjedna u okviru otvorenog ispitivanja.
Following completion of the 52-week active-controlled period, patients were eligible to enter a 4-week placebo-controlled period in which they were re-randomized to receive Fexeric (n=96) or placebo (n=96).
Nakon što je završilo razdoblje aktivne kontrole u trajanju od 52 tjedna, bolesnici su mogli početi s 4-tjednim placebom kontroliranim razdobljem u kojem su ponovno randomizirani za primanje Fexerica (n=96) ili placeba (n=96).
Following completion of the controlled phase of each of the Phase 3 trials, patients who were iron deficient and anaemic could be optionally retreated and receive two additional 510 mg intravenous injections of Rienso for a total cumulative dose of 2.04 g.
Nakon završetka kontrolirane faze u ta tri ispitivanja faze 3, bolesnici s manjkom željeza i anemijom mogli su se po izboru ponovno liječiti i primiti dvije dodatne intravenske injekcije od 510 mg lijeka Rienso do ukupne kumulativne doze od 2,04 g.
Following concomitant administration of a single dose bosutinib with six daily doses of 600 mg rifampicin, in 24 healthy subjects in fed state bosutinib exposure (Cmax and AUC in plasma) decreased to 14% and 6%, respectively, of the values when bosutinib 500 mg was administered alone.
Nakon istodobne primjene jedne doze bosutiniba i šest dnevnih doza od 600 mg rifampicina u 24 zdrava ispitanika u stanju sitosti, izloženost bosutinibu (Cmax i AUC u plazmi) smanjila se na 14% odnosno 6% vrijednosti u odnosu na primjenu 500 mg samog bosutiniba.
Following concomitant administration of a single dose of leflunomide to subjects receiving mult iple doses of rifampicin (non-specific cytochrome P450 inducer) A771726 peak levels were increased by approximately 40 %, whereas the AUC was not significantly changed.
Nakon istodobne primjene pojedinačne doze leflunomida u osoba koje su primale višestruke doze rifampicina (nespecifičnog induktora citokroma P450), vršne koncentracije A771726 porasle su za 40 %, dok se vrijednost AUC nije značajno promijenila.
Following concomitant administration of carbamazepine, a potent inducer of CYP3A4, the geometric means of Cmax and AUC for aripiprazole were 68 % and 73 % lower, respectively, compared to when aripiprazole (30 mg) was administered alone.
Nakon istodobne primjene karbamazepina, jakog induktora CYP3A4, geometrijski određena srednja vrijednost Cmax aripiprazola bila je manja za 68 %, a AUC-a za 73 % u usporedbi s onima kad se aripiprazol (30 mg) primjenjivao sam.
Following concomitant administration of carbamazepine, a potent inducer of CYP3A4, the geometric means of Cmax and AUC for aripiprazole were 68% and 73% lower, respectively, compared to when aripiprazole (30 mg) was administered alone.
Nakon istodobne primjene karbamazepina, jakog induktora CYP3A4, geometrijski određena srednja vrijednost Cmax aripiprazola bila je manja za 68 %, a AUC-a za 73 % u usporedbi s onima kad se aripiprazol (30 mg) primjenjivao sam.
Following concomitant administration of carbamazepine, a strong inducer of CYP3A4, and oral aripiprazole to patients with schizophrenia or schizoaffective disorder, the geometric means of Cmax and AUC for aripiprazole were 68 % and 73 % lower, respectively, compared to when oral aripiprazole (30 mg) was administered alone.
Nakon istodobne primjene karbamazepina, jakog induktora CYP3A4, i peroranog aripiprazola bolesnicima sa shizofrenijom ili shizoafektivnim poremećajem, geometrijska srednja vrijednost Cmax aripiprazola bila je 68 %, a AUC-a 73 % niža u usporedbi s onima kad se oralni aripiprazol (30 mg) primjenjivao sam.
Following consecutive application of two SANCUSO transdermal patches in healthy subjects, each for seven days, granisetron levels were maintained over the study period with evidence of minimal accumulation.
Nakon uzastopne primjene dvaju transdermalnih flastera SANCUSO u zdravih ispitanika, pri čemu je svaki nošen 7 dana, koncentracija granisetrona je održana uz minimalnu akumulaciju tijekom ispitivanja.
Following continuous intravenous infusion, the steady state serum concentration (Css) was achieved within a day and remained stable over time.
Nakon kontinuirane intravenske infuzije, koncentracija u serumu postigla je stanje ravnoteže (Css, od eng. steady state concentration) unutar jednog dana i ostala stabilna tijekom vremena.
Following conversion to any alternative formulation, therapeutic drug monitoring must be performed and dose adjustments made to ensure that systemic exposure to tacrolimus is maintained.
Nakon zamjene jednog farmaceuskog oblika drugim, potrebno je tijekom liječenja pratiti koncentraciju lijeka i prilagođavati dozu kako bi se održala jednaka sustavna izloženost takrolimusu.
Following coronary artery bypass graft surgery, patients administered Dynastat have a higher risk of adverse reactions such as: cardiovascular/ thromboembolic events (including myocardial infarction, stroke/TIA, pulmonary embolus, and deep vein thrombosis; see sections 4.3 and 5.1), deep surgical infections, and sternal wound healing complications.
Nakon operacije ugradnje arteriokoronarne premosnice, bolesnici kojima se primjenjuje Dynastat imaju povećan rizik od nuspojava kao što su: kardiovaskularni/tromboembolijski događaji (uključujući infarkt miokarda, moždani udar/TIA, plućna embolija i duboka venska tromboza; vidjeti dijelove 4.3 i 5.1), duboke kirurške infekcije i komplikacije s cijeljenjem sternalne rane.
Following coronary artery bypass graft surgery, patients administered Dynastat have a higher risk of adverse reactions such as: cardiovascular/thromboembolic events (including myocardial infarction, stroke/TIA, pulmonary embolus, and deep vein thrombosis; see sections 4.3 and 5.1), deep surgical infections, and sternal wound healing complications.
Nakon operacije ugradnje arteriokoronarne premosnice, bolesnici kojima se primjenjuje Dynastat imaju povećan rizik od nuspojava kao što su: kardiovaskularni/tromboembolijski događaji (uključujući infarkt miokarda, moždani udar/TIA, plućna embolija i duboka venska tromboza; vidjeti dijelove 4.3 i 5.1), duboke kirurške infekcije i komplikacije s cijeljenjem sternalne rane.
Following delivery
Nakon poroda
Following delivery or second-trimester abortion
Nakon poroda ili nakon pobačaja u drugom tromjesečju
Following dilution do not store above 25˚C
Nakon razrjeđivanja ne čuvati na temperaturi iznad 25˚C..
Following dilution the DARZALEX infusion should be intravenously administered at the appropriate initial infusion rate, as presented in Table 2 below.
Nakon razrjeđivanja, infuziju lijeka DARZALEX treba primijeniti intravenski uz odgovarajuću početnu brzinu, kako je navedeno u Tablici 2 u nastavku.
Following dilution, brivaracetam solution for injection/infusion was found to be physically compatible and chemically stable when mixed with the diluents listed in the section 6.6 for 24 hours and stored in PVC or polyolefin bags at temperature up to 25°C. From a microbiological point of view, the product should be used immediately after dilution.
Nakon razrjeđivanja, otopina brivaracetama za injekciju/infuziju pomiješana sa sredstvima za razrjeđivanje navedenima u dijelu 6.6 fizički je kompatibilna i kemijski stabilna 24 sata kada se čuva u PVC ili poliolefinskim vrećicama na temperaturi do 25°C. S mikrobiološkog stanovišta, lijek treba primijeniti odmah nakon razrjeđivanja.
Following discontinuation of fingolimod, lymphocyte count progressively returns to normal range within 1 to 2 months after stopping therapy.
Nakon prekida liječenja fingolimodom, broj limfocita progresivno se vraća u normalan raspon unutar 1 do 2 mjeseca nakon prestanka terapije.
Following discontinuation of NovoThirteen the patient’s neutrophil count returned to levels similar to those prior to treatment with NovoThirteen.
Nakon prekida primjene lijeka NovoThirteen broj neutrofila u bolesnika vratio se na razine slične onima prije liječenja lijekom NovoThirteen.
Following discontinuation of Revolade, platelet counts return to baseline levels within 2 weeks in the majority of patients, which increase the bleeding risk and in some cases may lead to bleeding.
Nakon prekida terapije lijekom Revolade, u većine bolesnika vrijednost trombocita vraća se na početnu vrijednost unutar 2 tjedna, što povisuje rizik od krvarenja, a u nekim slučajevima može dovesti i do krvarenja.
Following discontinuation of treatment, the majority of the elevations that had not resolved during treatment were reversible, with the creatinine levels of most subjects returning to Baseline or near- Baseline values.
Nakon prekida liječenja, većina povišenja koja se nije povukla tijekom liječenja bila je reverzibilna i razine kreatinina su se u većine ispitanika vratile na normalne ili gotovo normalne vrijednosti.
Following discontinuation of treatment, the majority of the elevations that had not resolved during treatment were reversible, with the creatinine levels of most subjects returning to baseline or near- baseline values.
Nakon prekida liječenja, većina povišenja koja se nije povukla tijekom liječenja bila je reverzibilna i razine kreatinina su se u većine ispitanika vratile na početne ili gotovo početne vrijednosti.
Following disease progression, patients were treated at the physician’s discretion with other anti-cancer interventions.
Nakon progresije bolesti, bolesnici su liječeni uz liječničku diskreciju drugim oblicima onkološkog liječenja.
Following doses of 1,200 mg/day, symptoms related to the central nervous system (e.g. dizziness) and the gastrointestinal system (e.g. nausea, vomiting) were observed and resolved with dose adjustments.
1200 mg/dan opaženi su simptomi vezani uz središnji živčani sustav (npr. omaglica) i gastrointestinalni sustav (npr. mučnina, povraćanje) i nestali bi s prilagođavanjem doze.
Following each of two intralesional administrations, separated by 24 hours, of Xiapex 0.58 mg into the penile plaque of 19 patients with Peyronie’s disease, plasma levels of AUX-I and AUX-II in patients with quantifiable levels (82% and 40% for AUX-I and AUX-II, respectively) were minimal and short-lived.
Nakon svake od ukupno dvije intralezijske primjene 0,58 mg Xiapexa u plak penisa u razmaku od 24 sata u 19 bolesnika s Peyronijevom bolešću, razine AUX-I i AUX-II u plazmi bolesnika s mjerljivim razinama (82% za AUX-I i 40% za AUX-II) bile su minimalne i kratkotrajne.
Following first-trimester abortion
Nakon pobačaja u prvom tromjesečju
Following Grade 3 or 4 diarrhoea, the subsequent dose of ONIVYDE should be reduced, (see section 4.2).
Nakon proljeva stupnja 3 ili 4, sljedeće doze lijeka ONIVYDE treba smanjiti (vidjeti dio 4.2).
Following HBeAg seroconversion, serologic response and clinical remission are generally durable after stopping lamivudine.
Nakon serokonverzije HBeAg, serološki odgovor i klinička remisija općenito traju i nakon prestanka uzimanja lamivudina.
Following identification of a stable dose of Revolade, perform full blood count (FBC) with white blood cell count (WBC) differential monthly.
Nakon postizanja stabilne doze lijeka Revolade, jednom mjesečno treba provoditi analizu kompletne krvne slike (KKS) i diferencijalne bijele krvne slike.
Following improvement to Grade ≤ 2, resume at reduced dose of 400 mg.
Nakon poboljšanja do ≤ 2. stupnja, nastaviti liječenje dozom smanjenom na 400 mg.
Following improvement to Grade ≤ 2, resume at reduced dose of 400 mg. treatment cycle, the dose may be further increased to 800 mg.
≤ 2. stupnja, nastaviti liječenje dozom smanjenom na 400 mg.
Following influenza vaccination, false positive results in serology tests using the ELISA method to detect antibodies against HIV1, Hepatitis C and especially HTLV1 have been observed.
Nakon cijepljenja protiv influence, zabilježeni su lažno pozitivni rezultati seroloških testova primjenom ELISA metode za detekciju protutijela protiv virusa HIV1, hepatitisa C i posebno virusa HTLV1.
Following influenza vaccination, false positive serology test results may be obtained by the ELISA method for antibody to human immunodeficiency virus-1 (HIV-1), hepatitis C virus and, especially, HTLV-1.
Nakon cijepljenja protiv influence mogu se dobiti lažno pozitivni rezultati serološkog određivanja protutijela metodom ELISA na virus humane imunodeficijencije-1 (HIV-1), virus hepatitisa C i, osobito, na HTLV-1.
Following influenza vaccination, false positive serology test results may be obtained by the ELISA method for antibody to human immunodeficiency virus-1 (HIV-1), hepatitis C virus and, especially, HTLV-1.
Nakon cijepljenja protiv influence, mogu se dobiti lažno pozitivni serološki rezultati testova metodom ELISA na protutijela na virus humane imunodeficijencije-1 (HIV-1), virus hepatitisa C i naročito, HTLV-1.
Following influenza vaccination, false positive serology test results may be obtained by the ELISA method for antibody to human immunodeficiency virus-1 (HIV-1), hepatitis C virus and, especially, human T-lymphotropic virus type 1 (HTLV-1).
Nakon cijepljenja protiv influence mogući su lažno pozitivni rezultati serološkog određivanja protutijela metodom ELISA na virus humane imunodeficijencije-1 (HIV-1), virus hepatitisa C i posebno, humanog T-limfotropičnog virusa tipa 1 (HTLV-1).
Following influenza vaccination, false positive serology test results may be obtained by the ELISA method for antibody to human immunodeficiency virus-1(HIV-1), hepatitis C virus and, especially, HTLV-1 have been observed.
Nakon cijepljenja protiv influence, mogu se dobiti lažno pozitivni serološki rezultati testova metodom ELISA na protutijela na virus humane imunodeficijencije-1(HIV-1), virus hepatitisa C i naročito, HTLV-1.
Following influenza vaccination, false-positive serology test results may be obtained by the ELISA method for antibody to human immunodeficiency virus-1 (HIV-1), hepatitis C virus and, especially, HTLV-1.
Nakon cijepljenja protiv influence mogu se dobiti lažno pozitivni rezultati seroloških testiranja metodom ELISA na protutijelo protiv virusa humane imunodeficijencije -1 (HIV-1), hepatitisa C i, osobito, virusa HTLV-1.
Following influenza vaccination, false-positive serology test results may be obtained by the ELISA method for antibody to human immunodeficiency virus-1 (HIV-1), hepatitis C virus and, especially, HTLV-1.
Nakon cijepljenja protiv influence zabilježeni su lažno pozitivni rezultati seroloških testova metodom ELISA za otkrivanje protutijela protiv virusa humane imunodeficijencije 1 (HIV1), hepatitisa C i osobito HTLV-1.
Following infusion, dip all teats with a disinfectant teat dip.
Nakon infundiranja umočite sve sise u tekućinu za dezinfekciju sisa.
Following infusion, peak concentrations of VWF markers (VWF:RCo, VWF:Ag, and VWF:CB) and FVIII:C were achieved immediately with a mean IR of 0.013-0.016 (IU/mL)/(IU/kg) for VWF markers and 0.017-0.021 (IU/mL)/(IU/kg) for FVIII:C. The elimination t1/2 of VWF markers was between 9.7 and 12.9 h whereas FVIII:C had a longer t1/2 of approximately 18 h due to a plateau effect that may represent the net effect of decreasing levels of exogenous FVIII, combined with increasing endogenous FVIII levels.
Vršne koncentracije VWF markera (VWF:RCo, VWF:Ag, i VWF:CB) i FVIII:C postignute su odmah nakon infuzije sa srednjom IR vrijednosti od 0,013-0,016 (IU/mL)/(IU/kg) za VWF markere i 0,017-0,021 (IU/mL)/(IU/kg) za FVIII:C. Eliminacijsko vrijeme poluživota VWF markera bilo je između 9,7 i 12,9 sati dok je FVIII:C imao duže poluvrijeme života, otprilike 18 sati, zbog plato-učinka koji može biti rezultat ukupnog učinka smanjenja razine egzogenog FVIII kombiniranog s povećanjem razine endogenog FVIII.
Following inhalation of Brimica Genuair 340/12 micrograms, aclidinium and formoterol showed terminal elimination half-lives of approximately 5 h and 8 h, respectively.
Nakon inhalacije Brimica Genuaira od 340/12 mikrograma, aklidinij i formoterol pokazali su terminalno poluvrijeme eliminacije od otprilike 5 sati, odnosno 8 sati.
Following inhalation of Duaklir Genuair 340/12 micrograms, aclidinium and formoterol showed terminal elimination half-lives of approximately 5 h and 8 h, respectively.
Nakon inhalacije Duaklir Genuaira od 340/12 mikrograma, aklidinij i formoterol pokazali su terminalno poluvrijeme eliminacije od otprilike 5 sati, odnosno 8 sati.
Following inhalation of these doses with the Breelib the maximum plasma concentrations (Cmax) and systemic exposures (AUC (0– tlast)) increased dose-proportionally.
Nakon inhalacije ovih doza pomoću uređaja Breelib, maksimalna koncentracija u plazmi (Cmax) i sistemska izloženost (AUC (0–tlast)) povećale su se proporcionalno dozi.
Following initial doses of rifampicin, a transient increase in ambrisentan AUC(0–τ) (121% and 116% after first and second doses of rifampicin, respectively) was observed, presumably due to a rifampicin-mediated OATP inhibition.
Nakon početnih doza rifampicina pronađen je prolazni porast AUC(0-τ) ambrisentana (121% u prvoj i 116% nakon druge doze rifampicina), vjerojatno zbog inhibicije OATP od strane rifampicina.
Following initial therapy, you will receive a standard pack containing 1 bottle of RAVICTI and a reclosable bottle cap adapter.
Nakon početne terapije dobit ćete standardno pakiranje koje sadrži 1 bocu lijeka RAVICTI i nastavak za bocu s čepom za ponovno zatvaranje.
Following initiation of indinavir/ritonavir 800/100 BID or lopinavir/ritonavir 400/100 BID, dose reduction of cyclosporine A to
Nakon započinjanja liječenja indinavirom/ritonavirom pri dozi od 800/100 BID ili lopinavirom/ritonavirom pri dozi od 400/100 BID u jednom je ispitivanju bilo potrebno smanjiti dozu ciklosporina A na
Following initiation of therapy, serum creatinine should be measured prior to each dose of zoledronic acid and treatment should be withheld if renal function has deteriorated.
Nakon početka terapije kreatinin u serumu treba mjeriti prije svake doze zoledronatne kiseline, a liječenje treba obustaviti ako se funkcija bubrega pogorša.
Following initiation of treatment, additional CE marked oral syringes compatible with the reclosable bottle cap adapter can be obtained from a pharmacy.
Nakon početka liječenja dodatne oralne štrcaljke s oznakom CE, kompatibilne s nastavkom za bocu s čepom za ponovno zatvaranje, mogu se nabaviti u ljekarni.
Following initiation of treatment, the pharmacy will provide a standard pack containing the medicinal product and reclosable bottle cap adapter.
Nakon početka liječenja, ljekarna će izdati standardno pakiranje koje sadrži lijek i nastavak za bocu s čepom za ponovno zatvaranje.
Following injection, pigs may have an increased rectal temperature of about 1.4 °C for up to two days, and in some pigs of up to 2.5 °C, but this should not last more than 24 hours after the injection.
Unutar 2 dana nakon injekcije, rektalna temperatura može porasti u prosjeku za otprilike 1,4 °C. Rijetko može doći do povećanja rektalne temperature za više od 2,5 °C, koje traje manje od 24 sata.
Following insertion in a pen, the cartridge and pen should be stored below 30C and should not be refrigerated.
Nakon umetanja u brizgalicu, uložak i brizgalicu čuvati na temperaturi ispod 30°C i ne odlagati u hladnjak.
Following intramuscular injection of TREVICTA at doses of 175-525 mg in the deltoid muscle, on average, an 11-12% higher Cmax was observed compared with injection in the gluteal muscle.
Nakon intramuskularne injekcije lijeka TREVICTA u dozama od 175- 525 mg u deltoidni mišić, zabilježena je prosječno 11-12% viša Cmax u usporedbi s injekcijom u glutealni mišić.
Following intravenous administration of 14C-radiolabeled regadenoson to rats and dogs, most radioactivity (85-96%) was excreted in the form of unchanged regadenoson.
Nakon intravenske primjene 14C-radioobilježenog regadenosona u štakora i pasa, najveći dio radioaktivnosti (85- 96%) izlučio se u obliku nepromijenjenog regadenosona.
Following intravenous administration of epoetin alfa in subjects with chronic renal failure, the volume of distribution ranged from 57-107 ml/kg after single dosing (12 IU/kg) to 42– 64 ml/kg after multiple dosing (48–192 IU/kg), respectively.
Nakon intravenske primjene epoetina alfa u ispitanika s kroničnim zatajenjem bubrega, volumen distribucije je bio u rasponu 57-107 ml/kg nakon jednokratne doze (12 IU/kg), odnosno 42-64 ml/kg nakon višestrukih doza (48-192 IU/kg).
Following intravenous administration of palonosetron 0.25 mg once every other day for 3 doses in 11 testicular cancer patients, the mean ( SD) increase in plasma concentration from Day 1 to Day 5 was 42  34 %.
U 11 bolesnika s rakom testisa, nakon intravenske primjene palonosetrona 0,25 mg jednom svaki drugi dan kroz 3 doze, prosječna vrijednost ( SD) porasta koncentracije u plazmi od 1. dana do 5. dana iznosila je 42  34%.
Following intravenous administration of topotecan at doses of 0.5 to 1.5 mg/m2 as a 30 minute infusion daily for five days, topotecan demonstrated a high plasma clearance of 62 l/h (SD 22), corresponding to approximately 2/3 of liver blood flow.
Nakon intravenske primjene topotekana u dozi od 0,5 do 1,5 mg/m2 u obliku 30-minutne infuzije dnevno tijekom 5 dana, topotekan je pokazao visoki klirens iz plazme u vrijednosti od 62 l/h (SD 22), koji odgovara približno 2/3 protoka krvi kroz jetru.
Following intravenous administration of Topotecan, at doses of 0.5 to 1.5 mg/m2 as a 30 minute infusion daily for five days, topotecan demonstrated a high plasma clearance of 62 l/h (SD 22), corresponding to approximately 2/3 of liver blood flow.
Nakon intravenske primjene topotekana u dozi od 0,5 do 1,5 mg/m2 u obliku 30-minutne infuzije dnevno tijekom 5 dana, topotekan je pokazao visoki klirens iz plazme u vrijednosti od 62 l/h (SD 22) koji odgovara približno 2/3 protoka krvi kroz jetru.
Following intravenous administration, approximately 58% of the administered radiolabelled dose (or 73% of the recovered radioactivity) was excreted in faeces by 192 hours post-dose.
Nakon intravenske primjene, približno 58% primijenjene radioaktivno označene doze (ili 73% pronađene radioaktivnosti) izlučilo se fecesom unutar 192 sata nakon primjene doze.
Following intravenous administration, approximately 58% of the administered radiolabelled dose (or 73% of the recovered radioactivity) was excreted in faeces by 192 hours post-dose.
Nakon intravenske primjene, približno 58% primijenjene radioaktivno označene doze (ili 73% pronađene radioaktivnosti) izlučilo se u feces unutar 192 sata nakon primjene doze.
Following intravenous administration, at the beginning most organs contained an amount of radioactivity which represented their content of 64Cu-laden blood.
Nakon intravenske primjene, na početku je većina organa sadržavala količinu radioaktivnosti koja je predstavljala količinu 64Cu u krvi.